This is not the first ADC-related acquisition for BMS this year as it builds its portfolio. Credit: Alpha Tauri 3D Graphics via www.shutterstock.com.

Bristol Myers Squibb (BMS) has signed another development deal focused on cancer therapeutics after acquiring the ORM-6151 programme from South Korean biotech Orum Therapeutics.

The agreement takes place less than a month after BMS’ high-profile acquisition of Mirati.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader to treat acute myeloid leukaemia (AML) and myelodysplastic syndromes. 

This acquisition validates Orum’s dual-precision targeted protein degradation approach, which involves the precision delivery of targeted protein degraders to cancer cells using antibody-drug conjugates (ADCs). The ORM-6151 programme is designed to target and degrade CD33, a protein found on the surface of certain cancer cells. 

BMS will pay an upfront amount of $100m, with the potential for milestone payments, taking the total deal value to $180m. 

Orum’s lead drug, called ORM-5029, is in Phase I clinical trials and targets HER2-expressing solid tumours in breast cancer patients. The company expects to complete the study in 2025. ADCs are targeted medicines that deliver chemotherapy agents to cancer cells. Rather than a toxin being used to target the cancer cells, Orum is using a small molecule designed to degrade target proteins. 

This is not the first ADC-related acquisition for BMS this year. In April, BMS gained exclusive rights to access the P5 conjugation platform from the Planegg, Germany-based Tubulis for the development of differentiated ADCs to treat cancer patients. The deal, which involved a $22.75m upfront payment, gave BMS sole responsibility for the development, production, and commercialisation of the resulting ADCs. 

According to GlobalData, the biopharmaceutical industry witnessed a 400% growth in total deal value of ADC-focused licensing agreements from 2017 to 2022 and reached a peak of $16.6bn in 2022. 

GlobalData is the parent company of Pharmaceutical Technology.